Please login to the form below
SCLC
This page shows the latest SCLC news and features for those working in and with pharma, biotech and healthcare.
Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
early-stage NSCLC, small cell lung cancer (SCLC) and hepatocellular carcinoma (HCC).
Latest news
-
EC approves Roche’s Tecentriq for early-stage lung cancer
Tecentriq was the first approved cancer immunotherapy for the first-line treatment of adults with extensive-stage small cell lung cancer (SCLC) in combination with chemotherapy.
-
AZ’s Imfinzi combination shows promise in liver cancer
Imfinzi is already used to treat unresectable, stage 3 non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (ES-SCLC) as well as advanced bladder cancer. ... The company has a broad development programme for Imfinzi plus
-
AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
AstraZeneca has announced that its PD-L1 inhibitor Imfinzi (durvalumab) showed a ‘sustained and clinically meaningful’ survival benefit for patients with extensive stage cell lung cancer (ES-SCLC). ... For treatment purpose, clinicians divide SCLC
-
New data advances AstraZeneca’s “revolution in oncology”
More Imfinzi data will be presented at the European Society for Medical Oncology (ESMO) Congress, showing three-year overall survival data in extensive-stage small cell lung cancer (ES-SCLC), the
-
Roche's Tecentriq reduces risk of disease recurrence or death by 34% in some NSCLC patients
Tecentriq is currently approved for the front-line treatment of small cell lung cancer (SCLC), a market where the checkpoint inhibitor has been able to carve a niche away from the ... SCLC is less common than NSCLC but tends to be more aggressive,
More from news
Approximately 6 fully matching, plus 42 partially matching documents found.
Latest Intelligence
-
Deal Watch February 2017
triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer.
-
Deal Watch April 2016
Rova-T showed a 44% overall response rate in DLL-expressing small cell lung cancer (SCLC) patients who had failed one or more standard therapies.
-
Deal Watch November 2015
July finalised a $730m exclusive deal with Boehringer Ingelheim for HM61713, an orally active third generation EGFR agent in small cell lung cancer (SCLC).
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
Bedrock Healthcare Communications
Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
